

<b>Supplemental digital content Table 1. Characteristics of patients with bacteremia and contaminated blood cultures</b>							
<b>Case</b>	<b>Age (mos)</b>	<b>LOS (hrs)</b>	<b>Organism</b>	<b>Penicillin Susceptibility</b>	<b>Initial Antibiotic</b>	<b>Blood Culture Directed Changes in Management</b>	<b>Discharge Antibiotic</b>
1	2.1	172	<i>Staphylococcus aureus</i> (MSSA) <sup>e</sup>	N/A	Clindamycin	Broadened to vancomycin and then narrowed to 1 <sup>st</sup> generation cephalosporin	1 <sup>st</sup> generation cephalosporin
2	3.4	226	<i>Staphylococcus aureus</i> (MRSA) <sup>e</sup>	N/A	Ceftriaxone	Broadened by adding clindamycin	Clindamycin & 3rd generation cephalosporin (IV)
3	4.7	51	Alpha streptococcus (not <i>S. pneumoniae</i> or <i>Enterococcus spp.</i> )*	N/A	Ampicillin	Broadened to ceftriaxone	Penicillin/amoxicillin
4	6.4	73	<i>Streptococcus pneumoniae</i>	R	Ceftriaxone	Broadened to linezolid and levofloxacin	Amoxicillin-clavulanate & levofloxacin
5	8.1	95	<i>Streptococcus pneumoniae</i>	S	Ceftriaxone	Narrowed to amoxicillin	Amoxicillin-clavulanate
6	9.6	237	<i>Staphylococcus aureus</i> (MSSA)	N/A	Vancomycin	No changes made	1 <sup>st</sup> generation cephalosporin (IV)
7	12.3	58	<i>Streptococcus pneumoniae</i>	S	Ceftriaxone	No changes made	Amoxicillin-clavulanate
8	13.3	367	<i>Haemophilus influenza</i> (beta-lactamase negative)	S	Ceftriaxone, metronidazole and vancomycin	Narrowed to 3 <sup>rd</sup> generation cephalosporin	None
9	13.8	130	<i>Streptococcus pneumoniae</i> <sup>a,b,d</sup>	S	Clindamycin, vancomycin, and ceftriaxone	No changes made	Vancomycin & 3rd generation cephalosporin (IV)
10	14.3	1454	<i>Staphylococcus aureus</i> (MRSA) <sup>a,b,c</sup>	N/A	Vancomycin and ceftriaxone	No changes made	Vancomycin (IV)
11	14.9	84	<i>Streptococcus</i>	Not reported	Vancomycin	Narrowed to 3 <sup>rd</sup>	Penicillin/amoxicillin

<b>Supplemental digital content Table 1. Characteristics of patients with bacteremia and contaminated blood cultures</b>							
<b>Case</b>	<b>Age (mos)</b>	<b>LOS (hrs)</b>	<b>Organism</b>	<b>Penicillin Susceptibility</b>	<b>Initial Antibiotic</b>	<b>Blood Culture Directed Changes in Management</b>	<b>Discharge Antibiotic</b>
			<i>pneumoniae</i> <sup>a,b</sup>			generation cephalosporin	
12	15.1	335	<i>Streptococcus pneumoniae</i> <sup>a,e</sup>	S	Ceftriaxone and vancomycin	Narrowed to 3 <sup>rd</sup> generation cephalosporin	3 <sup>rd</sup> generation cephalosporin
13	15.6	382	<i>Streptococcus pneumoniae</i> <sup>a,b</sup>	Not reported	Vancomycin	Narrowed to 3 <sup>rd</sup> generation cephalosporin	3 <sup>rd</sup> generation cephalosporin
14	19.6	14	<i>Abiotrophia species</i> *	N/A	Ceftriaxone	No changes made	Penicillin/amoxicillin
15	21.3	116	Coagulase negative staphylococcus*	N/A	Ampicillin	Broadened to clindamycin and ceftriaxone	3 <sup>rd</sup> generation cephalosporin
16	21.7	211	<i>Streptococcus pneumoniae</i> <sup>a,d,e</sup>	R	Clindamycin and ceftriaxone	Broadened to linezolid	Levofloxacin
17	22.2	182	<i>Streptococcus pneumoniae</i> <sup>a,b</sup>	Not reported	Cefuroxime and vancomycin	Narrowed to 2 <sup>nd</sup> generation cephalosporin	2 <sup>nd</sup> generation cephalosporin
18	22.5	280	Coagulase negative staphylococcus*	R	Ceftriaxone	Broadened by adding vancomycin and azithromycin	None
19	23.3	239	<i>Streptococcus pneumoniae</i>	S	Ceftriaxone	Broadened by adding clindamycin	Clindamycin
20	24.1	66	<i>Streptococcus pneumoniae</i>	S	Ampicillin	No changes made	Penicillin/amoxicillin
21	25.1	314	<i>Streptococcus pneumoniae</i> <sup>e</sup>	I	Ceftriaxone	Broadened by adding clindamycin	Clindamycin & 3 <sup>rd</sup> generation cephalosporin
22	27.8	44	<i>Streptococcus pneumoniae</i>	S	Ceftriaxone	No changes made	Amoxicillin-clavulanate
23	31.9	165	<i>Streptococcus pneumoniae</i>	R	Ceftriaxone	Broadened to	Vancomycin (IV)

<b>Supplemental digital content Table 1. Characteristics of patients with bacteremia and contaminated blood cultures</b>							
<b>Case</b>	<b>Age (mos)</b>	<b>LOS (hrs)</b>	<b>Organism</b>	<b>Penicillin Susceptibility</b>	<b>Initial Antibiotic</b>	<b>Blood Culture Directed Changes in Management</b>	<b>Discharge Antibiotic</b>
						vancomycin	
24	55.6	550	Coagulase negative staphylococcus*	N/A	Clindamycin and ceftriaxone	No changes made	None
25	55.9	59	<i>Streptococcus pneumoniae</i>	S	Ceftriaxone	No changes made	3 <sup>rd</sup> generation cephalosporin
26	60.3	46	Coagulase negative staphylococcus*	NA	Clindamycin and ceftriaxone	No changes made	Clindamycin & 3 <sup>rd</sup> generation cephalosporin
27	62.7	39	<i>Bacillus species</i> (not anthracis)*	N/A	Ceftriaxone	No changes made	3 <sup>rd</sup> generation cephalosporin
28	68.2	115	<i>Streptococcus pneumoniae</i>	S	Ceftriaxone	No changes made	3 <sup>rd</sup> generation cephalosporin
29	81.8	63	<i>Micrococcus luteus</i> *	N/A	Ampicillin and azithromycin	No changes made	Penicillin/amoxicillin & azithromycin
30	109.2	191	<i>Staphylococcus aureus</i> (MRSA) <sup>c, e</sup>	N/A	Azithromycin	Broadened by adding ceftriaxone and vancomycin	Clindamycin
31	125.7	53	<i>Streptococcus pneumoniae</i>	S	Ampicillin	Broadened to amoxicillin-clavulanate	Amoxicillin-clavulanate
32	129.7	69	<i>Streptococcus pneumoniae</i>	S	Ampicillin	No changes made	Penicillin/amoxicillin
33	156.9	179	<i>Staphylococcus aureus</i> <sup>c</sup> (MSSA)	N/A	Ceftriaxone, vancomycin, and clindamycin	Narrowed to oxacillin	Oxacillin (IV)
34	202.8	114	<i>Streptococcus pneumoniae</i>	S	Ceftriaxone	Broadened by adding azithromycin and vancomycin	Penicillin/amoxicillin

\*Determined to be contaminants

<sup>a</sup>Underwent pleural drainage procedure

<sup>b</sup>Initial complicated pneumonia

<sup>c</sup>Metastatic complications

<sup>d</sup>pleural fluid positive

<sup>e</sup>Presented with uncomplicated pneumonia and evolved to complicated pneumonia